Lesion Network MApping Navigated Continuous Theta-burst STimulation for Motor REcovery in Acute Ischemic Stroke

Prior treatment

• TMS contraindications include metallic foreign bodies in the head, pacemaker, implantable drug pumps, cochlear implants, etc.
• Participants in other clinical intervention studies within 30 days before randomization or who were participating in other clinical intervention studies.

Other illness

• Epilepsy or history of epilepsy, intracranial hypertension, tumor and other serious neurological disorders;
• Evidence of acute intracranial hemorrhage;
• A history of congenital or acquired hemorrhagic disease, coagulation factor deficiency, or thrombocytopenia disease;
• Patients with severe mental disorders or dementia who can not cooperate with informed consent and follow-up;
• Patients with malignancy or severe systemic disease and expected survival of less than 90 days;

Other

• Midline displacement and brain parenchymal mass effect seen in head CT and other images;
• Head CT or MRI showed bilateral acute cerebral infarction;
• After blood pressure control, the systolic blood pressure was still ≥180 mmHg or the diastolic blood pressure was ≥110 mmHg;
• Patients during pregnancy or lactation and within 90 days of planned pregnancy;
• Patients with ataxia (NIHSS 7 ≥ 1) and aphasia (NIHSS 9 ≥ 2).

• Age 18-80 years old.
• Acute ischemic stroke confirmed by CT or MRI at 14 days after onset.
• Pre-stroke modified Rankin scale (mRS) score≤1.
• 4≤NIHSS score≤ 25, 1a≤1, NIHSS5a/5b/6a/6b≥2 at least.
• Moderate or severe motor dysfunction (Fugl-Meyer motor score \< 80).
• Written informed consent from patients or their legally authorized representatives.